Merck (KGaA) Sells Women's Health Business to Teva for 285 million

Merck KGaA is a separate independent company from New Jersey Based Merck, so again watch and look for subsidiary actions here as ownership gets a little confusing at times. Merck KGaA is known as EMD Chemicals in the US, and outside of the US Merck in New Jersey is known as MSD, so are your confused now?

“EMD Millipore” is a division of Merck KGaA, Darmstadt, Germany and that acquisition was made earlier this year. Théramex is a Monaco-based pharmaceutical company.

Merck Buying Millipore in Massachusetts for $6 billion – Life Sciences and Chemicals Acquisition

Teva is one of the biggest and most aggressive generic drug companies that also has their own drugs in development too and they are headquartered in Israel. BD

German pharmaceutical major Merck KGaA (Merck) said that the company would sell its women's health unit Theramex to Israel's Teva Pharmaceutical Industries Ltd for €285 million ($389 million), in accordance with its strategy focused on core areas such as neurodegenerative diseases, oncology, fertility, rheumatology, endocrinology and cardiometabolic care.

Under the terms, Merck will sell its 100-per cent interest in Theramex SAM of Monaco and Theramex SpA of Italy to Teva. In addition, Merck will be eligible to receive certain performance-based milestone payments, the company said in a statement.

Teva Pharma Ad Campaign

The acquisition will provide Teva with a strong platform to expand its global women's health business and the contraceptive market.

Teva will have the distribution rights of Theramex products in certain countries including Spain and Brazil; Merck Serono will continue distributing Theramex products in certain other countries.

Merck acquired Theramex a decade ago, and since then it has developed a strong brand image, offering a large portfolio of women's health therapeutics in 50 countries, in the areas of gynecology, osteoporosis, menopause, and contraceptives. The company employs over 300 people.